Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy

Journal of Cellular and Molecular Medicine
Huimin BaiKeng Shen

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and tumoural heterogeneity (TH) has been blamed for treatment failure. The genomic and epigenomic atlas of EOC varies significantly with tumour histotype, grade, stage, sensitivity to chemotherapy and prognosis. Rapidly accumulating knowledge about the genetic and epigenetic events that control TH in EOC has facilitated the development of molecular-targeted therapy. Poly (ADP-ribose) polymerase (PARP) inhibitors, designed to target homologous recombination, are poised to change how breast cancer susceptibility gene (BRCA)-related ovarian cancer is treated. Epigenetic treatment regimens being tested in clinical or preclinical studies could provide promising novel treatment approaches and hope for improving patient survival.

References

Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·D V SantiC E Garrett
Aug 22, 1995·International Journal of Cancer. Journal International Du Cancer·A BellacosaJ R Testa
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T S FrankA Thomas
Jan 23, 1999·Nature Genetics·L ShayestehJ W Gray
Nov 21, 2000·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·P D SniegowskiA Shaver
Jan 5, 2002·Journal of the National Cancer Institute·John P GeislerRichard E Buller
Feb 8, 2002·Cell·Ashok R Venkitaraman
Sep 19, 2002·Journal of the National Cancer Institute·Jeffrey L HiltonRichard E Buller
Apr 15, 2003·Nature Medicine·Toshiyasu TaniguchiAlan D D'Andrea
Aug 2, 2003·Gynecologic Oncology·Mary L GemignaniJeff Boyd
Mar 3, 2004·The Journal of Pathology·Nathalie L G SiebenAdrienne M Flanagan
Jul 3, 2004·Cancer Research·Martin WidschwendterMelanie Ehrlich
Jul 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gillian GiffordRobert Brown
Oct 18, 2005·Molecular Cancer Therapeutics·Curtis BalchKenneth P Nephew
Aug 25, 2006·Molecular Cancer Therapeutics·Xiaozhong QianMichael Jeffers
Feb 27, 2007·Cell·Bradley E BernsteinEric S Lander
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
May 1, 2007·Current Opinion in Cell Biology·Michael Weber, Dirk Schübeler
Aug 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kylie L GorringeIan G Campbell
Sep 6, 2007·Cell Cycle·Lauren L Campbell, Kornelia Polyak
Oct 20, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J PattamadilokA Mutirangura
Feb 1, 2008·Gynecologic Oncology·Caroline A BartonPhilippa M O'Brien
Apr 17, 2008·British Journal of Cancer·S L LimJ A Green
Apr 24, 2008·Cancer Science·Ching-Tai LinMu-Hsien Yu
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eun Ji NamSunghoon Kim
Aug 21, 2008·Neoplasia : an International Journal for Oncology Research·Michael Wy ChanHuey-Jen L Lin
Sep 5, 2008·Annual Review of Pathology·Nader Chalhoub, Suzanne J Baker
Oct 1, 2008·Gynecologic Oncology·Antonio SorrentinoCristiano Ferlini
Nov 27, 2008·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Hui ZhangHao Yu

❮ Previous
Next ❯

Citations

Sep 2, 2016·Seminars in Cell & Developmental Biology·Hengbo ZhouHeide L Ford
Jul 20, 2018·Tumori·Hassan YousefiArdeshir Ghavamzadeh
Dec 19, 2018·Expert Reviews in Molecular Medicine·Ana BarbosaManuel R Teixeira
Jun 4, 2019·Journal of Cellular Physiology·Gailing LiGuijun Qin
Nov 21, 2017·Journal of Cellular Physiology·Leyla Norouzi-BaroughRasoul Salehi
Mar 12, 2017·Cancer Causes & Control : CCC·Rikki A CanniotoJoellen M Schildkraut
Nov 30, 2019·Clinical Epigenetics·Tzu-I WuHung-Cheng Lai
Apr 23, 2020·International Journal of Environmental Research and Public Health·Norhazlina Abdul WahabNorfilza Mohd Mokhtar

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR
xenografts
acetylation
xenograft

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Expert Opinion on Investigational Drugs
César Gómez-RaposoAndrés Redondo
Current Breast Cancer Reports
Shaveta Vinayak, James M Ford
Annals of Oncology : Official Journal of the European Society for Medical Oncology
S K SandhuJ de Bono
British Journal of Cancer
David Cibula, Judith Balmaña
© 2022 Meta ULC. All rights reserved